Advertisement
Advertisement

URGN

URGN logo

UroGen Pharma Ltd. Ordinary Shares

20.71
USD
Sponsored
-0.61
-2.88%
Jan 29, 16:00 UTC -5
Closed
exchange

After-Market

20.73

+0.02
+0.09%

URGN Earnings Reports

Positive Surprise Ratio

URGN beat 16 of 34 last estimates.

47%

Next Report

Date of Next Report
Mar 09, 2026
Estimate for Q4 25 (Revenue/ EPS)
$40.94M
/
-$0.50
Implied change from Q3 25 (Revenue/ EPS)
+48.96%
/
-27.54%
Implied change from Q4 24 (Revenue/ EPS)
+66.65%
/
-37.50%

UroGen Pharma Ltd. Ordinary Shares earnings per share and revenue

On Nov 06, 2025, URGN reported earnings of -0.69 USD per share (EPS) for Q3 25, beating the estimate of -0.70 USD, resulting in a 2.32% surprise. Revenue reached 27.48 million, compared to an expected 33.76 million, with a -18.58% difference. The market reacted with a +21.91% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.50 USD, with revenue projected to reach 40.94 million USD, implying an decrease of -27.54% EPS, and increase of 48.96% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
For Q3 2025, UroGen Pharma Ltd. Ordinary Shares reported EPS of -$0.69, beating estimates by 2.32%, and revenue of $27.48M, -18.58% below expectations.
The stock price moved up 21.91%, changed from $19.31 before the earnings release to $23.54 the day after.
The next earning report is scheduled for Mar 09, 2026.
Based on 10 analysts, UroGen Pharma Ltd. Ordinary Shares is expected to report EPS of -$0.50 and revenue of $40.94M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement